Built for Stability
Our Technology
Our Approach
The Technology Platform
AI + molecular-dynamics (FEP) pipeline to engineerstable growth factors
Phycin combines AI mutation scanning, molecular dynamics, and FEP analysis to identify stabilizing bFGF mutations, then advances the best candidates to wet-lab validation.
SynBio-enabled algae production platform
SynBio-enabled algae production platform uses expression vector design, transformation, selection, algae-based production, and protein purification to generate a clean final product. This workflow supports animal-free, endotoxin-free, and cost-efficient growth factor manufacturing.
PCT patent filed
Superior Stability
Expands applications and improves economics.
Regenerative therapies
Cell culture
Cosmetics
Cultivated meat
Phycin’s Ultrastable bFGF supports cold-chain-light logistics and longer shelf life, enables greater iPSC expansion than Wild-Type comparator conditions, and offers user-friendly handling with compatibility for 11+ freeze-thaw cycles, premixed formats, and automated workflows.
Phycin has an expanding IP portfolio and FTO strategy across its business lines
Ultrastable basic fibroblast growth factor variants and methods of use
Patent 1
PCT/US26/25294 — thermostable bFGF, composition of matter. Covers cell culture, wound healing, cosmetics, and cultivated meat.
Patent 2
US 18/674,768 — algae-based growth factor production. Covers recombinant production in algae for cell culture and cultivated meat.
Trademark
Algeline® (Reg. No. 6,103,131) — supports topical and consumer-product positioning.
